Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI302 Phase II Single-Arm Study in Neovascular AMD
ChiCTR2500113225Phase 2Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Nov 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efdamrofusp alfa in exudative macular degeneration, sponsored by Shanghai General Hospital. Primary endpoint: Proportion of participants with BCVA loss < 15 ETDRS letters at Week 52. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
efdamrofusp alfa
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2500113225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113225.